NBD AI Bulletin -- Shanghai Fosun Pharmaceutical (Group) Co., LTD announced on January 22 that the Company on January 21, 2021 received a notice from its controlling shareholder Fosun High Tech. According to the notice, the controlling shareholder has increased its holdings in the Company by more than 1%.

On December 1, 2020, the Company was notified that its controlling shareholder was to increase holdings at the right time within 12 months starting from December 1, 2020 (the day included) through centralized bidding, block trade or transfer agreement with capital no less than 100 million yuan but no more than 2% of the shares the Company issued as of December 1, 2020.

Shanghai Fosun Pharmaceutical's chairman Wu Yifang, 52 years old, graduated from China Nanjing University of Science and Technology with a major in international in 1996 and received a master's degree in business administration from Saint Joseph's University in the United States in 2005.

(By Gao Han)

Disclaimer: The content and data of this article are for reference only and do not constitute investment advice, verified before use. Any action you take upon the information on this website is at your own risk.